Haemoglobinopathy/Thalassaemia Screen
Haematology
Description
The Haemoglobinopathies are categorised into two main groups: the Haemoglobin Variants and the Thalassaemias. The Haemoglobin Variants (or Abnormal Haemoglobins) are a product of alteration in the globin protein structure, while the Thalassaemias are caused by under production of structurally normal globin protein.
Haemoglobinopathy/Thalassaemia Screening collates information from the FBC, Capillary Electrophoresis, ZPP, Sickle test and Gel Electrophoresis tests into a cohesive and accurate report on the patient’s haemoglobinopathy status, and in the ante-natal setting, can provide an indication of any risk to the fetus and ensure that this vital information is provided to the ante-natal team in order that the patient may be appropriately managed.
The NHS Sickle Cell and Thalassaemia Screening Programme requires that we are able to identify HbS, HbC, HbE, Hb D-Punjab, Hb O-Arab and Hb Lepore, but over 1300 Hb variants have been discovered, some of which can have altered Oxygen affinity or reduced stability. At Sheffield Teaching Hospitals NHSFT we use a Mass Spectrometric method to give a definitive identification of almost any Haemoglobin variant and have discovered several novel variants not previously described.
Indications
Sheffield is a ‘high prevalence’ trust as defined by the NHS Sickle Cell and Thalassaemia Screening Programme so all Ante Natal patients are offered Haemoglobinopathy Screening. We also undertake pre-selected screening from other ‘low prevalence’ areas.
Pre-operative sickle screening
Some Haemoglobin variants can interfere with other tests such as HbA1c measurement and alternative methods may be required for these patients.
Unexplained erythrocytosis
Sample Type
Whole blood (EDTA 4.0ml Lavender)
Reference Range
HbA2 1.5 - 3.4%, HbF <2.5%, ZPP 30-80 umol/mol Hb
Turnaround Time
Within 2 days
Testing Frequency
Mon-Fri
External Notes
Patients with a clinically significant haemoglobinopathy will be issued with a card.
References
NHS Sickle Cell and Thalassaemia Screening Programme: Handbook for antenatal laboratories version 4.2. October 2017
Please note: the above information is subject to change and we endeavour to keep this website up to date wherever necessary.
Your contact for this test
Jason Eyre BSc (Hons) Biomedical Science, FIBMS
Section Lead - Haemoglobinopathies and Red Cell Investigations
You are enquiring about
Haemoglobinopathy/Thalassaemia Screen